Table of Contents 2
List of Tables 4
List of Figures 4
Jyant Technologies, Inc. Spshot 5
Jyant Technologies, Inc. Overview 5
Key Information 5
Key Facts 5
Jyant Technologies, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Jyant Technologies, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Jyant Technologies, Inc. - Pipeline Products Glance 10
Jyant Technologies, Inc. - Clinical Stage Pipeline Products 10
Phase II Products/Combition Treatment Modalities 10
Jyant Technologies, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combition Treatment Modalities 11
Jyant Technologies, Inc. - Drug Profiles 12
JT-02 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
alvocidib hydrochloride 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
cisplatin 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
JT-03 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
JT-04 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
JT-05 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
JT-06 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
JT-07 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
JT-08 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Peptide to Antagonize Leptin Receptor II for Breast Cancer 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
resveratrol 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Jyant Technologies, Inc. - Pipeline Alysis 23
Jyant Technologies, Inc. - Pipeline Products by Target 23
Jyant Technologies, Inc. - Pipeline Products by Route of Administration 24
Jyant Technologies, Inc. - Pipeline Products by Molecule Type 25
Jyant Technologies, Inc. - Pipeline Products by Mechanism of Action 26
Jyant Technologies, Inc. - Locations And Subsidiaries 27
Head Office 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 28
Disclaimer 29